Fol­low­ing key late-stage ad­vances, BeiGene puts down $10M to get some dis­cov­ery projects rolling at Am­brx

Search­ing for a big­ger spot for it­self in the glob­al mar­ket weeks af­ter be­com­ing the first Chi­nese biotech to nab an FDA “break­through” des­ig­na­tion, BeiGene has en­list­ed the pro­tein en­gi­neers at Am­brx to add some dis­cov­ery projects to its can­cer pipeline.

The part­ners are paint­ing the deal in broad strokes, but they are clear about the $10 mil­lion San Diego-based Am­brx is get­ting to kick­start the col­lab­o­ra­tion. Its abil­i­ty to in­sert tR­NA/tR­NA syn­thetase pairs in­to cell lines, the com­pa­ny says, means it can em­pow­er ther­a­peu­tic pro­teins by plac­ing non-nat­ur­al amino acids at pre­cise po­si­tions. That lends it­self to ap­pli­ca­tions in both first-in-class con­ju­gates and op­ti­mized pep­tides, mon­o­clon­al an­ti­bod­ies and bi- or mul­ti-spe­cif­ic meds.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.